TNF and common variable immunodeficiency: The success of vedolizumab has been noted in patients with CVID and gut inflammation, however, its role in patients with concomitant CVID and UC specifically has not yet been described.19 We propose that providers consider escalating to non-TNF-alpha biologics, including vedolizumab, in patients with concomitant CVID and UC.